Latest From Antengene Corp.
UK pharma giant’s head, International tells Scrip expanded alliance with diversified Japan group will develop solutions across the patient journey, while new China investments aim to tap into emerging innovation in this market.
In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.
Private Company Edition: Biotech companies raised $3.9bn, down from $4.6bn in the first quarter of 2019 – a record-breaking year in the US – but dollars per deal stayed above $20m for a second year. Also, Fusion has April's second $100m-plus VC financing with a $105m Series B.
Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter.
- Therapeutic Areas
- Infectious & Viral Diseases
- Company Type
- Parent & Subsidiaries
- Antengene Corp.
- Senior Management
Jay Mei, MD, PhD, CEO
Hans de Haan, MD, PhD, CMO
John Chin, Chief Bus. Officer
- Contact Info
Phone: 21 3250 1095
Ste. 704, 999 West Zhongshan Rd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.